Duloxetine
Product Images NDC 60429-166

This is a medication label for a capsule containing duloxetine hydrochloride, which is equivalent to 20 mg duloxetine. It is a delayed-release capsule that comes with accompanying prescribing information. The medication should be dispensed in a tightly closed container and kept away from children. Pharmacists are advised to dispense the accompanying medication guide to each patient. The medication should be stored between 15-30°C (59-86°F) and is manufactured by Towa Pharmaceuticals Europe S.L and marketed by GSMS Incorporated.*

This is a description of a medication called DULoxetine Delayed-Release Capsules. Each capsule contains 33.7 mg of duloxetine hydrochloride USP equivalent to 30 mg duloxetine. The pharmacist should dispense the medication guide to each patient, which can be printed at https://gsms.us/. The dosage should be as directed in the accompanying Prescribing Information. The medication should be kept out of the reach of children and stored at 25°C (77°F). The medication is manufactured by Towa Pharmaceuticals Europe, S.L. and marketed by GSMS, Incorporated in Camarillo, CA 93012 USA.*

These are USP capsules for which a pharmacist must provide a medication guide to each patient. The medication guide can be printed from the website mentioned in the text. The capsules contain 67.3 mg of duloxetine hydrochloride USP, which is the equivalent of 60 mg of duloxetine. The dosage information can be found in the accompanying Prescribing Information. These capsules should be dispensed in a tightly closed container and kept out of reach of children. It is recommended to store them at 25°C (77°F) and they can be stored within a range of 15° to 30°C (59° to 86°F), as per the USP Controlled Room Temperature. These capsules are manufactured by Towa Pharmaceuticals Europe S.L. and marketed by GSMS, Incorporated in Camarillo, CA, and the latest revision was done on 06/22.*

The graph shows the proportion of patients with relapse over time for two treatments - Placebo and Duloxetine delayed-release. The treatment period is not specified.*

This graph displays the proportion of patients with relapse over time from randomization. The graph compares the proportion of patients with relapse between placebo and Duloxetine delayed-release capsules. The x-axis represents time in days, and the y-axis represents the proportion of patients with relapse. The Duloxetine delayed-release capsules group had a lower proportion of relapse than the placebo group.*

This is a table showing the percentage of patient improvement in pain from baseline. The table includes data for a medication called DUL 50 taken twice daily and also for DUL 50mg taken once daily, as well as placebo. The format of the table is not readable, so the actual percentages cannot be determined.*

This is a chart showing the percentage of patients improved in pain from baseline (BOCF) when taking placebo or DUL 60/120 mg once daily. The chart indicates that the percentage improvement is higher for DUL 60/120 mg once daily compared to placebo.*

The text provides a chart demonstrating the percentage of patients improved with placebo and Duloxetine 60 mg once daily. It also includes a list of numbers indicating percent improvement in pain from baseline using BOCF method.*